{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:22:18Z","timestamp":1791415338555,"version":"4.3.3"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Chronic myelogenous leukemia (CML) typically results from a reciprocal translocation between chromosomes 9 and 22 to produce the <jats:italic>bcr-abl<\/jats:italic> oncogene that when translated, yields the p210 BCR-ABL protein in more than 90% of all CML patients. This protein has constitutive tyrosine kinase activity that activates numerous downstream pathways that ultimately produces uncontrolled myeloid proliferation. Although the use of the BCR-ABL tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, dasatinib, bosutinib, and ponatinib have increased the overall survival of CML patients, their use is limited by drug resistance and severe adverse effects. Therefore, there is the need to develop novel compounds that can overcome these problems that limit the use of these drugs. Therefore, in this study, we sought to find novel compounds using Hypogen and Hiphip pharmacophore models based on the structures of clinically approved BCR-ABL TKIs. We also used optimal pharmacophore models such as three-dimensional queries to screen the ZINC database to search for potential BCR-ABL inhibitors. The hit compounds were further screened using Lipinski\u2019s rule of five, ADMET and molecular docking, and the efficacy of the hit compounds was evaluated. Our <jats:italic>in vitro<\/jats:italic> results indicated that compound ZINC21710815 significantly inhibited the proliferation of K562, BaF3\/WT, and BaF3\/T315I leukemia cells by inducing cell cycle arrest. The compound ZINC21710815 decreased the expression of p-BCR-ABL, STAT5, and Crkl and produced apoptosis and autophagy. Our results suggest that ZINC21710815 may be a potential BCR-ABL inhibitor that should undergo <jats:italic>in vivo<\/jats:italic> evaluation.<\/jats:p>","DOI":"10.3389\/fcell.2021.649434","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T06:10:36Z","timestamp":1614838236000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach"],"prefix":"10.3389","volume":"9","author":[{"given":"Ting-Ting","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Jia","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Nan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo-Xun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Charles R.","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Zhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40262-016-0391-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of Bosutinib.","volume":"55","author":"Abbas","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3390\/ph6060700","article-title":"Virtual lead identification of farnesyltransferase inhibitors based on ligand and structure-based pharmacophore techniques.","volume":"6","author":"Al-Balas","year":"2013","journal-title":"Pharmaceuticals (Basel)"},{"key":"B3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41586-018-0436-0","article-title":"The genetic basis and cell of origin of mixed phenotype acute leukaemia.","volume":"562","author":"Alexander","year":"2018","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.bmcl.2009.12.047","article-title":"Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.","volume":"20","author":"Aparoy","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/s1470-2045(07)70342-x","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1046\/j.1365-2257.2002.00413.x","article-title":"BCR\/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML).","volume":"24","author":"Arana-Trejo","year":"2002","journal-title":"Clin Lab Haematol"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1186\/s13321-014-0051-5","article-title":"Stereoselective virtual screening of the ZINC database using atom pair 3D-fingerprints.","volume":"7","author":"Awale","year":"2015","journal-title":"J. Cheminform."},{"key":"B8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1747-0285.2009.00911.x","article-title":"AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance.","volume":"75","author":"Azam","year":"2010","journal-title":"Chem. Biol. Drug Des."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/jco.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.","volume":"27","author":"Baccarani","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/sj.leu.2404533","article-title":"Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.","volume":"21","author":"Barnes","year":"2007","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/jci35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.","volume":"119","author":"Bellodi","year":"2009","journal-title":"J. Clin. Invest."},{"key":"B12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11030-013-9425-2","article-title":"Identification of dual Acetyl-CoA carboxylases 1 and 2 inhibitors by pharmacophore based virtual screening and molecular docking approach.","volume":"17","author":"Bhadauriya","year":"2013","journal-title":"Mol. Divers."},{"key":"B13","doi-asserted-by":"publisher","first-page":"16170","DOI":"10.1074\/jbc.272.26.16170","article-title":"Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.","volume":"272","author":"Bhat","year":"1997","journal-title":"J. Biol. Chem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"951","DOI":"10.4161\/cbt.28931","article-title":"SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.","volume":"15","author":"Bu","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"B15","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077390","article-title":"Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.","volume":"8","author":"Bucur","year":"2013","journal-title":"PLoS One"},{"key":"B17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2741\/278","article-title":"Suppression of autophagy by BCR\/ABL.","volume":"4","author":"Calabretta","year":"2012","journal-title":"Front. Biosci. (Schol Ed)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1021\/acs.jcim.5b00540","article-title":"Discovery of 2-Acylaminothiophene-3-Carboxamides as multitarget inhibitors for BCR-ABL kinase and microtubules.","volume":"55","author":"Cao","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.18632\/oncotarget.692","article-title":"All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.","volume":"3","author":"Cassuto","year":"2012","journal-title":"Oncotarget"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1182\/blood.v95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.","volume":"95","author":"Coutre","year":"2000","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ajh.21914","article-title":"Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment.","volume":"86","author":"Crowley","year":"2011","journal-title":"Am. J. Hematol."},{"key":"B22","author":"Crowley","year":"2016","journal-title":"Detecting Cleaved Caspase-3 in Apoptotic Cells by Flow Cytometry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1182\/blood.v94.3.1108.415k07_1108_1112","article-title":"STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells.","volume":"94","author":"de Groot","year":"1999","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia.","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"the molecular biology of chronic myeloid leukemia.","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000019150","article-title":"Clinical efficacy and safety of imatinib treatment in children and adolescents with chronic myeloid leukemia: a single-center experience in China.","volume":"99","author":"Deng","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s11427-018-9324-y","article-title":"Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.","volume":"61","author":"Dong","year":"2018","journal-title":"Sci. China Life Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s00894-011-1187-0","article-title":"3D-QSAR based pharmacophore modeling and virtual screening for identification of novel pteridine reductase inhibitors.","volume":"18","author":"Dube","year":"2012","journal-title":"J. Mol. Model."},{"key":"B29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ajh.23428","article-title":"Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.","volume":"88","author":"Elzinga","year":"2013","journal-title":"Am. J. Hematol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.ccr-06-0980","article-title":"Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.","volume":"12","author":"Fiskus","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","article-title":"Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.","volume":"111","author":"Gontarewicz","year":"2008","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.2174\/092986708786848578","article-title":"Targeted drugs in chronic myeloid leukemia.","volume":"15","author":"Gora-Tybor","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1073\/pnas.0408283102","article-title":"A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.","volume":"102","author":"Gumireddy","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.canlet.2016.09.025","article-title":"PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.","volume":"383","author":"Gupta","year":"2016","journal-title":"Cancer Lett."},{"key":"B35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.canlet.2019.11.040","article-title":"Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.","volume":"472","author":"Gupta","year":"2020","journal-title":"Cancer Lett."},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-016-0129-y","article-title":"Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.","volume":"14","author":"Halbach","year":"2016","journal-title":"Cell Commun. Signal."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening.","volume":"47","author":"Halgren","year":"2004","journal-title":"J. Med. Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/sj.leu.2404189","article-title":"BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry.","volume":"20","author":"Hamilton","year":"2006","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00432-017-2557-5","article-title":"Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR\/Integrin beta1\/Src signaling in triple negative breast cancer cells.","volume":"144","author":"Hamurcu","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1182\/blood-2011-01-330621","article-title":"Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML.","volume":"118","author":"Helgason","year":"2011","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2174\/1573406411208061117","article-title":"3D QSAR pharmacophore modeling for c-Met kinase inhibitors.","volume":"8","author":"Huang","year":"2012","journal-title":"Med. Chem."},{"key":"B42","doi-asserted-by":"publisher","first-page":"8804","DOI":"10.1038\/sj.onc.1206028","article-title":"Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.","volume":"21","author":"Huang","year":"2002","journal-title":"Oncogene"},{"key":"B43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/ci049714%2B","article-title":"ZINC\u2013a free database of commercially available compounds for virtual screening.","volume":"45","author":"Irwin","year":"2005","journal-title":"J. Chem. Inf. Model."},{"key":"B44","first-page":"1890","article-title":"Sorting and biological characteristics analysis for side population cells in human primary hepatocellular carcinoma.","volume":"6","author":"Jiang","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/812148","article-title":"Ligand based pharmacophore modeling and virtual screening studies to design novel HDAC2 inhibitors.","volume":"2014","author":"Kandakatla","year":"2014","journal-title":"Adv. Bioinform."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1158\/1535-7163.mct-07-0179","article-title":"Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia.","volume":"7","author":"Katsoulas","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.biosystems.2015.10.005","article-title":"Pharmacophore modeling, virtual screening, molecular docking studies and density functional theory approaches to identify novel ketohexokinase (KHK) inhibitors.","volume":"138","author":"Kavitha","year":"2015","journal-title":"Biosystems"},{"key":"B48","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.18632\/oncotarget.2837","article-title":"HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.","volume":"6","author":"Kim","year":"2015","journal-title":"Oncotarget"},{"key":"B50","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2174\/157489206778776907","article-title":"Second generation Abl kinase inhibitors and novel compounds to eliminate the Bcr-Abl\/T315I clone.","volume":"1","author":"Kimura","year":"2006","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"B51","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/aps.2015.17","article-title":"Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling.","volume":"36","author":"Kumar","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"B52","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s12031-018-1162-7","article-title":"HIF-1alpha\/Beclin1-mediated autophagy is involved in neuroprotection induced by hypoxic preconditioning.","volume":"66","author":"Lu","year":"2018","journal-title":"J. Mol. Neurosci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00432-014-1845-6","article-title":"Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.","volume":"141","author":"Machova Polakova","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"542","DOI":"10.4161\/auto.4600","article-title":"How to interpret LC3 immunoblotting.","volume":"3","author":"Mizushima","year":"2007","journal-title":"Autophagy"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24162870","article-title":"Discovery of novel DPP-IV inhibitors as potential candidates for the treatment of type 2 Diabetes mellitus predicted by 3D QSAR pharmacophore models, molecular docking and de novo evolution.","volume":"24","author":"Musoev","year":"2019","journal-title":"Molecules"},{"key":"B56","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood.v84.9.2912.2912","article-title":"Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.","volume":"84","author":"Nichols","year":"1994","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1182\/blood.v88.11.4304.bloodjournal88114304","article-title":"Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin.","volume":"88","author":"Oda","year":"1996","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.can-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089080","article-title":"Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.","volume":"9","author":"Okabe","year":"2014","journal-title":"PLoS One"},{"key":"B61","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.csbj.2019.02.006","article-title":"Ligand-based pharmacophore modeling, virtual screening and molecular docking studies for discovery of potential topoisomerase I inhibitors.","volume":"17","author":"Pal","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"B62","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1016\/j.bmcl.2015.08.013","article-title":"Expanding the structural diversity of Bcr-Abl inhibitors: hybrid molecules based on GNF-2 and Imatinib.","volume":"25","author":"Pan","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B63","first-page":"602","article-title":"[Annexin V for flow cytometric detection of phosphatidylserine expression on lymphoma cells undergoing apoptosis].","volume":"32","author":"Peng","year":"2001","journal-title":"Hua Xi Yi Ke Da Xue Xue Bao"},{"key":"B64","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1007\/s00894-012-1436-x","article-title":"Molecular interactions of c-ABL mutants in complex with imatinib\/nilotinib: a computational study using linear interaction energy (LIE) calculations.","volume":"18","author":"Pereira","year":"2012","journal-title":"J. Mol. Model."},{"key":"B65","year":"1971"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/leu.2008.80","article-title":"Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.","volume":"22","author":"Quint\u00e1s-Cardama","year":"2008","journal-title":"Leukemia"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1021\/acsomega.9b02263","article-title":"Discovery of Lonafarnib-like compounds: pharmacophore modeling and molecular dynamics studies.","volume":"5","author":"Rampogu","year":"2020","journal-title":"ACS Omega"},{"key":"B68","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/2105610","article-title":"Sulfonanilide derivatives in identifying novel aromatase inhibitors by applying docking, virtual screening, and MD simulations studies.","volume":"2017","author":"Rampogu","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7120563","article-title":"Discovery of potential plant-derived peptide deformylase (PDF) inhibitors for multidrug-resistant bacteria using computational studies.","volume":"7","author":"Rampogu","year":"2018","journal-title":"J. Clin. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.","volume":"5","author":"Ren","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.","volume":"56","author":"Ren","year":"2013","journal-title":"J. Med. Chem."},{"key":"B72","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/s0301-472x(99)00148-4","article-title":"CrkL functions as a nuclear adaptor and transcriptional activator in Bcr-Abl-expressing cells.","volume":"28","author":"Rhodes","year":"2000","journal-title":"Exp. Hematol."},{"key":"B73","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1747-0285.2012.01339.x","article-title":"Ligand-based virtual screening and molecular docking studies to identify the critical chemical features of potent cathepsin D inhibitors.","volume":"80","author":"Sakkiah","year":"2012","journal-title":"Chem. Biol. Drug Des."},{"key":"B75","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejmech.2017.07.031","article-title":"Heme oxygenase-1: a new druggable target in the management of chronic and acute myeloid leukemia.","volume":"142","author":"Salerno","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.4161\/auto.5.7.9509","article-title":"Targeted therapies and autophagy: new insights from chronic myeloid leukemia.","volume":"5","author":"Salomoni","year":"2009","journal-title":"Autophagy"},{"key":"B77","doi-asserted-by":"publisher","first-page":"23255","DOI":"10.1074\/jbc.271.38.23255","article-title":"The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene.","volume":"271","author":"Senechal","year":"1996","journal-title":"J. Biol. Chem."},{"key":"B78","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.3324\/haematol.2018.194431","article-title":"Autophagic degradation determines the fate of T315I-mutated BCR-ABL protein.","volume":"104","author":"Shinohara","year":"2019","journal-title":"Haematologica"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s00405-013-2394-3","article-title":"Antitumor effects of Dasatinib on laryngeal squamous cell carcinoma in vivo and in vitro.","volume":"270","author":"Song","year":"2013","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1586\/14737140.8.9.1387","article-title":"Abl tyrosine kinase inhibitors for overriding Bcr-Abl\/T315I: from the second to third generation.","volume":"8","author":"Tanaka","year":"2008","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B81","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.18632\/oncotarget.23231","article-title":"Ovatodiolide targets chronic myeloid leukemia stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K\/AKT\/mTOR pathway.","volume":"9","author":"Tu","year":"2018","journal-title":"Oncotarget"},{"key":"B82","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/s0140-6736(02)07679-1","article-title":"BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.","volume":"359","author":"von Bubnoff","year":"2002","journal-title":"Lancet"},{"key":"B83","article-title":"Aurora A kinase inhibitor AKI603 induces cellular senescence in chronic myeloid leukemia cells harboring T315I mutation.","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"B84","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.18632\/oncotarget.806","article-title":"STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia.","volume":"3","author":"Warsch","year":"2012","journal-title":"Oncotarget"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/sj.leu.2401598","article-title":"Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone.","volume":"13","author":"Winter","year":"1999","journal-title":"Leukemia"},{"key":"B86","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/aps.2013.180","article-title":"Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.","volume":"35","author":"Wu","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"B87","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.neuint.2009.09.008","article-title":"3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design.","volume":"56","author":"Ye","year":"2010","journal-title":"Neurochem. Int."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18091865","article-title":"Monitoring and measuring autophagy.","volume":"18","author":"Yoshii","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/leu.2012.65","article-title":"Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells.","volume":"26","author":"Yu","year":"2012","journal-title":"Leukemia"},{"key":"B90","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1038\/leu.2015.42","article-title":"Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.","volume":"29","author":"Zabriskie","year":"2015","journal-title":"Leukemia"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1021\/mp900163d","article-title":"Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter.","volume":"6","author":"Zheng","year":"2009","journal-title":"Mol. Pharm."},{"key":"B93","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11899-018-0474-6","article-title":"Chronic myeloid Leukemia: beyond BCR-ABL1.","volume":"13","author":"Zhou","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.649434\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T06:10:52Z","timestamp":1614838252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.649434\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":93,"alternative-id":["10.3389\/fcell.2021.649434"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2021.649434","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"article-number":"649434"}}